고형암 (전체)

ADCBiologicstaleShanghai Henlius BiotechPhase 1

HLX42 (HLX42)

Solid Tumor and NSCLC · Solid Tumor and NSCLC

#SolidTumorandNSCLC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

ADCBiologicstaleShanghai Henlius BiotechPhase 1

HLX48 (HLX48)

Advanced/Metastatic Solid Tumors · Advanced/Metastatic Solid Tumors

#AdvancedMetastaticSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

AntibodystaleHanmi Pharmaceutical Company Li…Phase 1

HM95573, cetuximab (HM95573, cetuximab)

Locally Advanced Solid Tumor; Metastatic Solid Tumor · Locally Advanced Solid Tumor

#LocallyAdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3

CGTBiologicstaleTCRCure Biopharma Ltd.Phase 1

HPV E6-specific TCR-T cells (HPV E6-specific TCR-T cells)

Cervical Cancer; Head and Neck Squamous Cell Carcinoma · Cervical Cancer

#CervicalCancer#CGT#Phase1#세포유전치료#CAR-T+3

AntibodystaleRochePhase 2

trastuzumab (Herceptin, Herceptin+XELOX)

Metastatic or Recurrent Gastric Adenocarcinoma; Her-2 Positive Gastric Cancer · Metastatic or Recurrent Gastric Adenocar

#MetastaticorRecurrentGastricAden#Antibody#Phase2#항체#면역항체+3

AntibodystaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 + nivolumab)

Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#항체#면역항체+3

AntibodystaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 and nivolumab)

Urothelial Carcinoma; Urothelial Carcinoma Bladder · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#항체#면역항체+3

CGTBiologicstaleGenovn Therapeutics (Suzhou) Co…Phase 1

IL-15 enhanced engineered NK cells (IL-15 enhanced engineered NK cells)

Solid Tumors; Metastatic Cancer · Solid Tumors

#SolidTumors#CGT#Phase1#세포유전치료#CAR-T+3

AntibodystaleGregory DanielsPhase 2

nivolumab (Opdivo, IL-2 and Nivolumab)

Melanoma Stage Iv; Renal Cell Carcinoma, Metastatic · Melanoma Stage Iv

#MelanomaStageIv#Antibody#Phase2#항체#면역항체+4

ADCBiologicstaleImmunoGen, Inc.Phase 2

IMGC936 (IMGC936)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 0%임상시험 1상태 ACTIVE

ADCBiologicstaleImmunoGen, Inc.Phase 1

IMGN289 (IMGN289)

EGFR Positive Solid Tumors · EGFR

#EGFR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

AntibodystaleImmuneering CorporationPhase 2

Treatment Group E (IMM-1-104 + pembrolizumab, IMM-1-104 + pembrolizumab (Treatment Group E))

Advanced Solid Tumor; Pancreatic Adenocarcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+3

AntibodystaleAssociazione Volontari Pazienti…Phase 3

INDUCTION CTx (TPF, INDUCTION CTx, INDUCTION CTx(TPF)+(RT+CETUXIMAB))

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2

ADCBiologicstaleInnate PharmaPhase 1

IPH4502 (IPH4502)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

AntibodystaleAstraZenecaPhase 1

durvalumab (Imfinzi, IPH5401 and Durvalumab)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#항체#면역항체+2

AntibodystaleMerckPreclinical

pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab (Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab))

Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Squamous Cell Carcinoma (ESCC

#EsophagealSquamousCellCarcinomaE#Antibody#Preclinical#항체#면역항체+2

AntibodystaleUniversity Medical Center Groni…Preclinical

durvalumab (Imfinzi, Immunotherapy: adjuvant durvalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Preclinical#항체#면역항체+4

AntibodystaleJanssenPhase 2

Infliximab + Prednisone (Infliximab + Prednisone)

Renal Cell Carcinoma; Melanoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#항체#면역항체+3

효능 ORR 6%임상시험 1상태 DISCONTINUED

AntibodystaleSir Run Run Shaw HospitalPhase 2

Ipalolimab and Tovorilimab (Ipalolimab and Tovorilimab)

dMMR/MSI-H-type Rectal Adenocarcinoma · dMMR/MSI-H-type Rectal Adenocarcinoma

#dMMRMSI-H-typeRectalAdenocarcino#Antibody#Phase2#항체#면역항체+4